265 related articles for article (PubMed ID: 26663722)
1. Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells.
Ye C; Geng Z; Dominguez D; Chen S; Fan J; Qin L; Long A; Zhang Y; Kuzel TM; Zhang B
J Immunol; 2016 Jan; 196(2):915-23. PubMed ID: 26663722
[TBL] [Abstract][Full Text] [Related]
2. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells.
Selamnia M; Mayeur C; Robert V; Blachier F
Biochem Pharmacol; 1998 Apr; 55(8):1241-5. PubMed ID: 9719479
[TBL] [Abstract][Full Text] [Related]
3. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV
Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858
[TBL] [Abstract][Full Text] [Related]
4. α-Difluoromethylornithine suppresses inflammatory arthritis by impairing myeloid-derived suppressor cells.
Geng Z; Ming B; Hu S; Dong L; Ye C
Int Immunopharmacol; 2019 Jun; 71():251-258. PubMed ID: 30927735
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW
Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253
[TBL] [Abstract][Full Text] [Related]
6. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine.
Heston WD; Kadmon D; Lazan DW; Fair WR
Prostate; 1982; 3(4):383-9. PubMed ID: 6812032
[TBL] [Abstract][Full Text] [Related]
7. Influence of gastrin, gastrin receptor blockers, epidermal growth factor, and difluoromethylornithine on the growth and the activity of ornithine decarboxylase of colonic carcinoma cells.
Eggstein S; Imdahl A; Kohler M; Waibel M; Farthmann EH
J Cancer Res Clin Oncol; 1991; 117(1):37-42. PubMed ID: 1997467
[TBL] [Abstract][Full Text] [Related]
8. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
9. Comparative antitumor properties in rodents of irreversible inhibitors of L-ornithine decarboxylase, used as such or as prodrugs.
Claverie N; Mamont PS
Cancer Res; 1989 Aug; 49(16):4466-71. PubMed ID: 2501026
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice.
Lan L; Trempus C; Gilmour SK
Cancer Res; 2000 Oct; 60(20):5696-703. PubMed ID: 11059762
[TBL] [Abstract][Full Text] [Related]
11. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract][Full Text] [Related]
12. Effects of three irreversible inhibitors of ornithine decarboxylase on macrophage-mediated tumoricidal activity and antitumor activity in B16F1 tumor-bearing mice.
Bowlin TL; Hoeper BJ; Rosenberger AL; Davis GF; Sunkara PS
Cancer Res; 1990 Aug; 50(15):4510-4. PubMed ID: 2114941
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy.
Geck RC; Foley JR; Murray Stewart T; Asara JM; Casero RA; Toker A
J Biol Chem; 2020 May; 295(19):6263-6277. PubMed ID: 32139506
[TBL] [Abstract][Full Text] [Related]
14. The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.
Ignatenko NA; Zhang H; Watts GS; Skovan BA; Stringer DE; Gerner EW
Mol Carcinog; 2004 Apr; 39(4):221-33. PubMed ID: 15057874
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
16. Effect of the ornithine decarboxylase inhibitor alpha, alpha-difluoromethylornithine on phorbol diester-induced inhibition of murine B lymphocyte differentiation.
Schuman LD; Baxter CS; Petro TM
Cancer Lett; 1989 Sep; 47(1-2):11-9. PubMed ID: 2517589
[TBL] [Abstract][Full Text] [Related]
17. The effect of tumor burden on ornithine decarboxylase activity in mice.
Saydjari R; Alexander RW; Upp JR; Poston GJ; Barranco SC; Townsend CM; Thompson JC
Cancer Invest; 1991; 9(4):415-9. PubMed ID: 1884248
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of human breast adenocarcinoma cells made resistant to alpha-difluoromethylornithine.
Das B; Vig M; Khurana KK; Madhubala R
Cancer Invest; 2000; 18(2):115-22. PubMed ID: 10705873
[TBL] [Abstract][Full Text] [Related]
19. Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity.
Kim DJ; Roh E; Lee MH; Oi N; Lim DY; Kim MO; Cho YY; Pugliese A; Shim JH; Chen H; Cho EJ; Kim JE; Kang SC; Paul S; Kang HE; Jung JW; Lee SY; Kim SH; Reddy K; Yeom YI; Bode AM; Dong Z
Cancer Res; 2016 Mar; 76(5):1146-1157. PubMed ID: 26676750
[TBL] [Abstract][Full Text] [Related]
20. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
